BIOLOGY · MITOCHONDRIA & CELLULAR ENERGY

One objective distal respiratory signal defines a question—not a shared diagnosis.

A formal buccal-cell assay shows low Complex IV relative to citrate synthase, preserved Complex I relative to citrate synthase, elevated citrate synthase, and a high Complex I-to-IV ratio. A separate blood test shows low free and total carnitine. Those measurements motivate a distal-throughput hypothesis; they do not prove systemic mitochondrial disease, acyl overflow, or one mechanism across cases.

Review the evidence See the exact tissue metrics →Test the throughput model →Connect to the 2026 neural study →

CASE-LEVEL EVIDENCE

Two observations, separated by evidence strength.

The direct respiratory-chain assay and the caregiver-reported Complex I history are presented separately because their specimens, methods, and evidentiary status are not equivalent. Neither establishes a shared mitochondrial diagnosis across the cohort.

01DIRECT ASSAY

Formal Complex IV–weighted buccal-cell signal

One de-identified LoF case has a formal buccal-cell respiratory-chain report: citrate synthase was 228% of the laboratory mean, RC-IV/CS was 38% of mean and below range, RC-I/CS was 88% of mean and within range, and the RC-I:RC-IV ratio was 51. A separate blood panel documented low free and total carnitine with a high esterified-to-free ratio.

This research-use/LDT result came from one tissue and one testing window. The report states that RC-I assay validation was incomplete and recommends repeat testing. It does not establish primary, systemic, brain, or ASH1L-caused mitochondrial disease.

02REPORTED CLINICAL HISTORY

Caregiver-reported Complex I diagnosis and treatment response

A newer case history reports secondary mitochondrial dysfunction or Complex I deficiency, low carnitine, regression before age six, and broad gains after treatment began near age six.

The ASH1L finding is a missense VUS and the record contains other molecular findings, so this case remains an attribution control. The primary respiratory-chain report, specimen, method, metabolic-genetics interpretation, treatment regimen, and longitudinal measurements are still needed.

OBJECTIVE TISSUE ANCHOR · EVIDENCE TIER F

The measured pattern is disproportionate Complex IV limitation in one buccal sample.

These are the report’s exact ratios, activity, reference intervals, and laboratory-relative percentages. Buccal cells are a peripheral tissue sample; epithelial purity and equivalence to airway, oral, GI, vascular, or brain tissue were not measured.

Citrate synthaseABOVE RANGE

27.63

228% of laboratory mean

Reference 4.4–22 nmol/min/mg buccal protein

RC-IV / CSBELOW RANGE

0.118

38% of laboratory mean

Reference 0.15–0.60

RC-I / CSWITHIN RANGE

6.0

88% of laboratory mean

Reference 3.4–11.9

RC-I : RC-IVABOVE RANGE

Calculated from reported ratios: 50.85

Report interval 12.1–30.3

MEASURED

A relative distal mismatch in this specimen

RC-IV/CS was below the report interval while RC-I/CS remained within range, yielding an RC-I:RC-IV ratio of 51. This supports the phrase disproportionate distal constraint in the tested buccal sample.

LABORATORY INTERPRETATION

Elevated mitochondrial content, possibly compensatory

The laboratory interpreted elevated citrate synthase as increased mitochondrial content and described compensation as possible. PGC-1α, TFAM, mitochondrial DNA copy number, and biogenesis rate were not measured.

REPORT BOUNDARY

Research-use assay requiring repeat

The report was signed November 22, 2023, identified the method as a laboratory-developed test, stated that RC-I assay validation was incomplete, and recommended repeat testing within six months. No repeat MITOswab is present in the supplied corpus.

SEPARATE BLOOD TEST · 4 AUGUST 2023 · EVIDENCE TIER F

The carnitine buffer was already abnormal in that testing window.

These measurements came from blood, not the buccal respiratory-chain specimen. Their co-occurrence supports paired follow-up but does not establish that the Complex IV ratio caused the carnitine pattern.

Free carnitine14 µmol/LLow · reference 25–55

Total carnitine32 µmol/LLow · reference 35–90

Esterified carnitine18 µmol/LWithin range · reference 4–36

Esterified / free ratio1.3High · reference 0.1–0.8

Precision: esterified carnitine itself was within range. The esterified-to-free ratio was high because free carnitine was low. This was not a species-resolved acylcarnitine panel and does not directly demonstrate “acyl parking.”

HOW TO READ THE ASSAYS

The label names the measurement—not the cause.

Complex I

The caregiver-reported history names Complex I, but the primary report, specimen, method, and interpretation remain pending.

Complex IV

The direct buccal assay reported low RC-IV relative to citrate synthase. One ratio in one specimen does not define whole-body respiratory function.

Citrate synthase normalization

The report normalized respiratory-complex activity to citrate synthase. High CS changes the denominator and may reflect mitochondrial content; it is not a direct PGC-1α or TFAM measurement.

DISTAL ETC THROUGHPUT → ACYL OVERFLOW? · EVIDENCE TIER X

The “exit traffic jam” is a falsifiable model—not the report’s conclusion.

If distal electron transfer becomes limiting during a defined physiological load, upstream redox pressure could rise and secondarily alter substrate oxidation. The direction and magnitude depend on tissue, substrate, coupling, severity, and state; the current human records do not demonstrate this chain.

01
Defined load window
Fasting, illness, anesthesia, exertion, sensory stress, or another state must be documented before sampling.
02
Distal clearance limit?
If Complex IV throughput becomes limiting, electron transfer to oxygen could lag relative to upstream input.
03
Upstream redox pressure?
A more reduced NADH or Q pool and altered ROS production are predictions to measure—not results of this buccal assay.
04
Acyl-CoA buffering shift?
Acylcarnitine formation can buffer excess acyl-CoA and regenerate free CoA; a changed species pattern would not by itself localize the defect.
05
Delayed recovery?
The decisive phenotype is the return curve: respiratory, redox, metabolic, epithelial, vascular, and functional baselines after the load ends.

WHAT WOULD SUPPORT IT

Repeated state-matched respiratory measurements; NADH/NAD⁺ and Q redox state; oxygen consumption and ATP; ROS and nitric-oxide handling; free CoA and carnitine pools; species-resolved acylcarnitines; and a reproducible recovery curve.

WHAT WOULD WEAKEN IT

No reproducible distal defect, a normal state-matched redox and acylcarnitine profile, a stronger alternative diagnosis, absence of temporal coupling, or failure of allele correction to rescue the phenotype in a relevant cell model.

LANE-SPECIFIC COMPARATORS

Three records answer three different biochemical questions.

The lanes remain separate by analyte, specimen, source depth, and molecular context. They are not summed as independent proof of one ASH1L bioenergetic mechanism.

01F · DIRECT RECORD

Female · loss-of-function

Distal respiratory-chain tissue anchor

Buccal CS, RC-IV/CS, RC-I/CS, and RC-I:RC-IV are quantified above; a separate blood test quantified carnitine.

This is the only current objective tissue-level anchor for the distal-throughput question. It is not proof of a systemic Complex IV lesion or acyl overflow.

02R · REPORTED FORMAL CONTENT

De-identified comparator · molecular context withheld

Reported species-specific acylcarnitine comparator

A caregiver reports a species-specific acylcarnitine flag and exclusion of the corresponding primary organic-acid disorder.

The value, interval, specimen, state, and primary report are pending. An isolated reported species cannot localize an ETF, CoQ, respiratory-chain, or tissue-level defect and is intentionally not linked to a public age, sex, variant class, or multisystem dossier.

03F · VERIFICATION BOUNDARY

Male · frameshift loss-of-function

C14-family lane is not currently positive

The visible formal serum-panel entry is C14:1 at 0.00 µmol/L. The separate saturated C14 line and its interval are not recoverable from the current extract.

C14 and C14:1 are not interchangeable. No C14 “spike,” long-chain FAO defect, or match to the buccal Complex IV pattern is claimed unless the original missing line is recovered.

Current conclusion: one reported acylcarnitine flag remains a muted, record-pending comparator. A separate formal long-chain panel does not verify a positive match. “Same highway, same exit” remains a research hypothesis and cannot be presented as a three-case convergence.

SYSTEMIC COROLLARIES · CASES KEPT SEPARATE

Interface and endothelial signals can guide assays without being assigned to the buccal result.

The observations below come from different people and evidence layers. Their value is in defining tissue-specific measurements and recovery curves—not in implying that one Complex IV result already explains them.

BUCCAL-ANCHOR CASE · RECORD-BACKED + PARENT-OBSERVED

Mucosal, ENT, and GI interface

Recovered MRI content documents right mastoid effusion, ethmoid/maxillary sinus inflammation, and mild adenoidal hypertrophy.
Recovered stool content includes lysozyme 677 and secretory IgA 289, with calprotectin below 10 and lactoferrin 1.9.
Late-off mucus, illness co-flares, and post-anesthesia worsening are parent-observed chronology—not a formal clearance assay.

These findings prioritize epithelial repair, ion/fluid handling, mucociliary behavior, and return-to-baseline measurement. They do not establish impaired glymphatic or visceral clearance.

CROSS-RECORD IMMUNE / HEMOSTATIC / URINARY CONTENT

Separate compartments—not one endothelial dossier

Across separate formal and reported records, cytokine panels contain both outlying and within-range components.
Hemostatic testing, bruising, skin, and repair concerns appear in other records and require their own hematology and tissue interpretation.
Urinalysis findings, nonconfirmatory cultures, culture-positive infection, and later controls are distributed across records rather than published as one person-level sequence.

These records define candidate immune, hemostatic, urinary, and repair measurements. They do not prove persistent inflammation, ROS/NO imbalance, endothelial injury, or a shared Complex IV mechanism; repeatability, state, primary reports, and ordinary competing causes remain necessary.

DIRECT ASH1L EXPERIMENT · 2026

Human-neuron data make mitochondrial function a testable ASH1L question.

The peer-reviewed Yale-led study perturbed 23 neurodevelopmental genes, including ASH1L, across neural progenitors, immature glutamatergic neurons, mature glutamatergic neurons, and mature GABAergic neurons. Convergent networks were strongest in mature glutamatergic neurons and included mitochondrial biology.

Read the Nature Neuroscience paper ↗

Pooled membrane-potential screen

ASH1L knockout was among the perturbations producing an increased mitochondrial membrane-potential signal in neural progenitors and mature glutamatergic neurons.

Arrayed respiratory testing

When ASH1L knockout neurons were tested separately, Seahorse measures of coupled and maximal respiration did not show significant change.

Interpretive boundary

This was complete gene knockout in experimental cells. It does not measure graded residual dosage, classify a patient allele, explain a buccal Complex IV result, or support treatment use.

WIDER BIOENERGETIC SIGNAL REGISTER

Other records help define when and what to measure.

These observations support structured follow-up. None is specific enough to establish mitochondrial disease on its own.

Lactate and liver-test history

A separate caregiver history describes recurring elevated lactate and liver tests; direct reports and event-state timing are not currently available.

Urine pyruvate snapshot

One formal organic-acid panel showed pyruvic acid slightly above that report’s interval, with urine lactic acid within range and most displayed analytes within range or below detection.

Acylcarnitine profiling

Species-resolved, state-defined repeat panels are needed. A reported flag and separate formal long-chain entries represent different biochemical lanes and cannot be merged into one generic elevation.

Fuel-sensitive states

Low intake, fasting, ketosis or hypoglycemia histories, dehydration, vomiting, constipation, illness, heat, and prolonged recovery identify when paired metabolic sampling may be most informative.

PROSPECTIVE STUDY DESIGN

Pair the right sample with the person’s state.

01
Recover and harmonize prior reports. Record specimen, method, complexes assayed, normalization, reference population, illness/fasting state, medications, and the laboratory interpretation.
02
Define whether the question is primary or secondary dysfunction. Integrate mitochondrial and nuclear genomic testing with metabolic-genetics review; screening markers alone lack adequate specificity.
03
Measure stable baseline and a clinically meaningful state. Pair lactate/pyruvate handling, amino and organic acids, acylcarnitines, carnitine, CK, CMP and relevant physiologic measures with symptoms and recovery.
04
Connect human findings to allele-aware models. Test residual ASH1L dosage, membrane potential, morphology, OXPHOS protein, oxygen consumption, ATP production, redox state, and rescue in prioritized cell types.

Mitochondrial Medicine Society consensus ↗GeneReviews: Primary mitochondrial disorders ↗Open research questions →